To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect.

First page of article

Psychedelic compounds (psilocybin, lysergic acid diethylamide, ayahuasca) paired with psychotherapy offer great potential for addressing multiple aspects of unmet palliative care needs for aging patients with Alzheimer disease and their caregivers. In this review, the authors integrate recent findings from psychedelic and psychedelic-assisted therapy clinical research with key domains of Alzheimer disease palliative care, from neurobehavioral symptom management to social and spiritual aspects of care in patients and their caregivers. In doing so, they provide a framework for approaching use of these exciting compounds in the Alzheimer disease population, while recognizing some of the practical challenges faced.

To access this article, please choose from the options below

Purchase access to this article

Claim Access

If you are a current subscriber with Society Membership or an Account Number, claim your access now.

Subscribe to this title

Purchase a subscription to gain access to this and all other articles in this journal.

Institutional Access

Visit ScienceDirect to see if you have access via your institution.


Linked Articles

Unknown widget #d2170c4d-a9cf-482f-ac17-ef77d57a1866

of type linkedContentList

Related Articles

Unknown widget #c2ffda61-8426-42f7-926b-03d7330eede2

of type relatedArticleListWidget